<!DOCTYPE html>

<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Prostaglandins, Leukotrienes & PAF - Essentials of Medical Pharmacology</title>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
tex: {
inlineMath: [['$', '$'], ['\\(', '\\)']],
displayMath: [['$$', '$$'], ['\\[', '\\]']],
processEscapes: true,
processEnvironments: true
},
svg: { fontCache: 'global' },
options: {
skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
}
};
</script>

<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>

</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
<span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
<span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
<div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->

<nav class="floating-toc" id="floating-toc">
<div class="floating-toc-header">
<span>üìë</span> Table of Contents
</div>
<ul class="floating-toc-list">
<li><a href="#introduction">Overview</a></li>
<li><a href="#biosynthesis">Biosynthesis & Degradation</a></li>
<li><a href="#cox-isoforms">COX-1 vs COX-2</a></li>
<li><a href="#actions">Pharmacological Actions</a></li>
<li><a href="#leukotrienes">Leukotrienes</a></li>
<li><a href="#receptors">Receptors & Mechanisms</a></li>
<li><a href="#uses">Clinical Uses</a></li>
<li><a href="#paf">Platelet Activating Factor</a></li>
<li><a href="#case-study">Case Study</a></li>
</ul>
</nav>

<div class="page-wrapper">
<div class="container">
<article class="document-article">
<header class="document-header">
<div class="header-badge">
<span>üî¨</span>
<span>Topic 14</span>
</div>
<h1 class="document-title">Prostaglandins, Leukotrienes (Eicosanoids) and Platelet Activating Factor</h1>
<div class="title-meta">
<div class="meta-item">
<span>üìö</span>
<span>Autacoids and Related Drugs</span>
</div>
<div class="meta-item">
<span>‚è±Ô∏è</span>
<span>40 min read</span>
</div>
</div>
</header>

<main id="main-content" class="content-wrapper">
            <!-- Section 1: Introduction -->
            <section class="content-section" id="introduction">
                <div class="section-header">
                    <div class="section-number">01</div>
                    <h2 class="section-title">
                        <span class="title-icon">üß¨</span>
                        Overview
                    </h2>
                </div>

                <div class="content-card">
                    <p>Prostaglandins (PGs) and Leukotrienes (LTs) are biologically active derivatives of 20 carbon atom polyunsaturated essential fatty acids that are released from cell membrane phospholipids. They are collectively called <strong>Eicosanoids</strong> (eicosa = 20).</p>
                    <p>Unlike hormones, there are no preformed stores of PGs and LTs. They are synthesized locally in response to stimuli and act locally (autacoids). Practically every cell and tissue is capable of synthesizing one or more types of PGs or LTs.</p>
                    <div class="callout callout--note">
                        <div class="callout-header">
                            <span class="callout-icon">üí°</span>
                            <h4 class="callout-title">Historical Note</h4>
                        </div>
                        <div class="callout-content">
                            <p>The term 'prostaglandin' was coined in the 1930s assuming they were derived from the prostate. In the 1970s, it was discovered that aspirin-like drugs act by inhibiting PG synthesis. Bergstrom, Samuelsson, and Vane received the Nobel Prize in 1982 for their work on PGs and LTs.</p>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Section 2: Biosynthesis -->
            <section class="content-section" id="biosynthesis">
                <div class="section-header">
                    <div class="section-number">02</div>
                    <h2 class="section-title">
                        <span class="title-icon">‚öóÔ∏è</span>
                        Chemistry, Biosynthesis & Degradation
                    </h2>
                </div>

                <div class="content-card">
                    <p>In human tissues, the fatty acid released from membrane lipids in largest quantity is <strong>5, 8, 11, 14-eicosatetraenoic acid (Arachidonic acid)</strong>. This is the main precursor. The rate of synthesis is governed by the rate of release of arachidonic acid from membrane lipids by <em>Phospholipase A2</em>.</p>
                    
                    <h3>Two Major Pathways</h3>
                    <div class="grid grid-2">
                        <div class="grid-item">
                            <h4>1. Cyclooxygenase (COX) Pathway</h4>
                            <p>Generates eicosanoids with a ring structure:</p>
                            <ul>
                                <li><strong>Prostaglandins (PGs):</strong> $PGE_2$, $PGF_{2\alpha}$</li>
                                <li><strong>Prostacyclin:</strong> $PGI_2$</li>
                                <li><strong>Thromboxane:</strong> $TXA_2$</li>
                            </ul>
                        </div>
                        <div class="grid-item">
                            <h4>2. Lipoxygenase (LOX) Pathway</h4>
                            <p>Generates open chain compounds:</p>
                            <ul>
                                <li><strong>Leukotrienes (LTs):</strong> $LTB_4$, $LTC_4$, $LTD_4$, $LTE_4$</li>
                                <li><strong>Lipoxins</strong></li>
                            </ul>
                        </div>
                    </div>

                    <figure class="content-figure" data-lightbox="true">
                        <div class="figure-image-wrapper">
                            <img src="../../../../../assets/images/image-20251214-51e2f647.jpeg" alt="Biosynthesis of prostaglandins and leukotrienes" class="figure-image">
                            <div class="figure-overlay">
                                <span class="overlay-icon">üîç</span>
                                <span class="overlay-text">Click to enlarge</span>
                            </div>
                        </div>
                        <figcaption class="figure-caption">Fig. 13.1: Biosynthesis of prostaglandins (PGs) and leukotrienes (LTs). NSAIDs inhibit COX pathway; Zileuton inhibits LOX pathway.</figcaption>
                    </figure>

                    <p><strong>Degradation:</strong> Occurs rapidly in most tissues, fastest in lungs. Plasma $t_{1/2}$ is few seconds to minutes. $PGI_2$ is catabolized mainly in the kidney.</p>
                </div>
            </section>

            <!-- Section 3: COX Isoforms -->
            <section class="content-section" id="cox-isoforms">
                <div class="section-header">
                    <div class="section-number">03</div>
                    <h2 class="section-title">
                        <span class="title-icon">üîÑ</span>
                        COX-1 and COX-2 Isoforms
                    </h2>
                </div>

                <div class="content-card">
                    <p>Cyclooxygenase (COX) exists in two major isoforms. Understanding their roles is crucial for understanding the action of NSAIDs.</p>
                    
                    <div class="table-responsive">
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Feature</th>
                                    <th>COX-1 (Constitutive)</th>
                                    <th>COX-2 (Inducible)</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>Nature</strong></td>
                                    <td>Constitutive (present in basal state)</td>
                                    <td>Inducible (normally minute, increases in inflammation)</td>
                                </tr>
                                <tr>
                                    <td><strong>Function</strong></td>
                                    <td>Physiological "House keeping"</td>
                                    <td>Pathological / Inflammatory</td>
                                </tr>
                                <tr>
                                    <td><strong>Key Roles</strong></td>
                                    <td>Gastric mucus secretion<br>Haemostasis (Platelets)<br>Renal function maintenance</td>
                                    <td>Inflammation<br>Pain<br>Fever<br>Cancer (cell proliferation)</td>
                                </tr>
                                <tr>
                                    <td><strong>Exceptions</strong></td>
                                    <td></td>
                                    <td>Constitutive in Brain, Kidney, Foetus</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>

                    <div class="callout callout--info">
                        <div class="callout-header">
                            <span class="callout-icon">‚ÑπÔ∏è</span>
                            <h4 class="callout-title">COX-3</h4>
                        </div>
                        <div class="callout-content">
                            <p>A splice variant of COX-1, designated <strong>COX-3</strong>, has been found in dog brain. It is inhibited by paracetamol and may explain its central antipyretic/analgesic action, though its exact role in humans is still under investigation.</p>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Section 4: Pharmacological Actions -->
            <section class="content-section" id="actions">
                <div class="section-header">
                    <div class="section-number">04</div>
                    <h2 class="section-title">
                        <span class="title-icon">‚öôÔ∏è</span>
                        Actions & Pathophysiological Roles
                    </h2>
                </div>

                <div class="content-card">
                    <p>The actions vary depending on the specific PG and the tissue involved. Key actions are summarized below.</p>

                    <h3>1. Cardiovascular System</h3>
                    <ul class="enhanced-list">
                        <li class="list-item"><strong>$PGE_2$:</strong> Vasodilatation in most beds; fall in BP.</li>
                        <li class="list-item"><strong>$PGF_{2\alpha}$:</strong> Constricts larger veins and pulmonary arteries.</li>
                        <li class="list-item"><strong>$PGI_2$ (Prostacyclin):</strong> Potent vasodilator (generated by vascular endothelium).</li>
                        <li class="list-item"><strong>$TXA_2$ (Thromboxane):</strong> Potent vasoconstrictor (generated by platelets).</li>
                        <li class="list-item"><strong>Ductus Arteriosus:</strong> $PGE_2$ maintains patency during fetal life. NSAIDs can induce closure.</li>
                    </ul>

                    <h3>2. Platelets</h3>
                    <div class="grid grid-2">
                        <div class="grid-item">
                            <h4>$TXA_2$ (Pro-aggregatory)</h4>
                            <p>Produced by platelets (COX-1). Potent inducer of aggregation and release reaction.</p>
                        </div>
                        <div class="grid-item">
                            <h4>$PGI_2$ (Anti-aggregatory)</h4>
                            <p>Produced by endothelium (COX-2). Potent inhibitor of aggregation. Constitutes a balance with TXA2.</p>
                        </div>
                    </div>
                    <p><strong>Aspirin Role:</strong> Irreversibly acetylates platelet COX-1. Since platelets cannot regenerate enzyme (no nucleus), thromboxane synthesis is blocked for the life of the platelet (~7 days), causing an antithrombotic effect.</p>

                    <h3>3. Uterus</h3>
                    <p>$PGE_2$ and $PGF_{2\alpha}$ consistently contract human uterus (pregnant and non-pregnant). They soften the cervix (cervical priming). They are involved in dysmenorrhoea and initiation of labour.</p>

                    <h3>4. Bronchi</h3>
                    <ul class="enhanced-list">
                        <li class="list-item"><strong>Constrictors:</strong> $PGF_{2\alpha}$, $PGD_2$, $TXA_2$, Cysteinyl Leukotrienes ($LTC_4, LTD_4$).</li>
                        <li class="list-item"><strong>Dilators:</strong> $PGE_2$, $PGI_2$.</li>
                        <li class="list-item"><strong>Aspirin-induced asthma:</strong> Inhibition of COX diverts arachidonic acid to LOX pathway $\rightarrow$ excess Leukotrienes $\rightarrow$ bronchoconstriction.</li>
                    </ul>

                    <h3>5. Stomach</h3>
                    <p>$PGE_2$ and $PGI_2$ (via COX-1) are natural ulcer protectives. They decrease acid secretion, increase mucus/bicarbonate secretion, and improve mucosal blood flow. NSAIDs cause ulcers by blocking this protective mechanism.</p>

                    <h3>6. Kidney</h3>
                    <p>$PGE_2$ and $PGI_2$ increase water and electrolyte excretion (diuretic effect) and cause renal vasodilatation. They regulate renal blood flow. NSAIDs can cause Na+/water retention and counteract diuretics.</p>
                </div>
            </section>

            <!-- Section 5: Leukotrienes -->
            <section class="content-section" id="leukotrienes">
                <div class="section-header">
                    <div class="section-number">05</div>
                    <h2 class="section-title">
                        <span class="title-icon">ü¶†</span>
                        Leukotrienes (LTs)
                    </h2>
                </div>

                <div class="content-card">
                    <p>Produced via the <strong>5-Lipoxygenase (5-LOX)</strong> pathway.</p>
                    <div class="table-responsive">
                        <table class="comparison-table">
                            <thead>
                                <tr>
                                    <th>Leukotriene</th>
                                    <th>Function</th>
                                    <th>Clinical Relevance</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td><strong>$LTB_4$</strong></td>
                                    <td>Potent Chemotactic agent</td>
                                    <td>Attracts neutrophils/monocytes to inflammation site.</td>
                                </tr>
                                <tr>
                                    <td><strong>$LTC_4, LTD_4$</strong><br>(Cysteinyl LTs)</td>
                                    <td>SRS-A (Slow Reacting Substance of Anaphylaxis)</td>
                                    <td>Bronchoconstriction, increased vascular permeability, mucus secretion. Major mediators in Asthma.</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </section>

            <!-- Section 6: Receptors -->
            <section class="content-section" id="receptors">
                <div class="section-header">
                    <div class="section-number">06</div>
                    <h2 class="section-title">
                        <span class="title-icon">üì°</span>
                        Receptors & Mechanisms
                    </h2>
                </div>

                <div class="content-card">
                    <p>All prostanoid receptors are G-protein coupled. They are grouped into Contractile, Relaxant, and Inhibitory types.</p>
                    
                    <ul class="enhanced-list">
                        <li class="list-item"><strong>DP ($PGD_2$):</strong> Relaxant ($DP_1$, $\uparrow$ cAMP) or Inhibitory ($DP_2$, $\downarrow$ cAMP).</li>
                        <li class="list-item"><strong>EP ($PGE_2$):</strong>
                            <ul>
                                <li>$EP_1$: Contractile ($G_q \rightarrow IP_3/DAG \rightarrow Ca^{2+}$).</li>
                                <li>$EP_2, EP_4$: Relaxant ($G_s \rightarrow \uparrow$ cAMP).</li>
                                <li>$EP_3$: Inhibitory ($G_i \rightarrow \downarrow$ cAMP), decreased lipolysis, gastric acid.</li>
                            </ul>
                        </li>
                        <li class="list-item"><strong>FP ($PGF_{2\alpha}$):</strong> Contractile (Uterus, Eye).</li>
                        <li class="list-item"><strong>IP ($PGI_2$):</strong> Relaxant (Vasodilatation, anti-platelet).</li>
                        <li class="list-item"><strong>TP ($TXA_2$):</strong> Contractile (Platelet aggregation, vasoconstriction).</li>
                    </ul>
                </div>
            </section>

            <!-- Section 7: Clinical Uses -->
            <section class="content-section" id="uses">
                <div class="section-header">
                    <div class="section-number">07</div>
                    <h2 class="section-title">
                        <span class="title-icon">üíâ</span>
                        Clinical Uses of PGs
                    </h2>
                </div>

                <div class="content-card">
                    <p>Clinical application is restricted due to short duration, cost, and side effects. However, they are valuable in specific niches.</p>

                    <div class="grid grid-2">
                        <div class="grid-item">
                            <h4>1. Abortion & Labour</h4>
                            <ul>
                                <li><strong>Mifepristone + Misoprostol ($PGE_1$):</strong> Medical termination of pregnancy (MTP) up to 7 weeks (highly successful).</li>
                                <li><strong>Carboprost (15-methyl $PGF_{2\alpha}$):</strong> Control of Postpartum Hemorrhage (PPH) due to uterine atony (2nd line to oxytocin/ergometrine).</li>
                                <li><strong>Dinoprostone ($PGE_2$):</strong> Cervical priming (softening) before induction of labour.</li>
                            </ul>
                        </div>
                        <div class="grid-item">
                            <h4>2. Glaucoma</h4>
                            <p><strong>Latanoprost, Travoprost, Bimatoprost ($PGF_{2\alpha}$ analogues):</strong> Topical eye drops increase uveoscleral outflow. First choice drugs for wide angle glaucoma.</p>
                        </div>
                        <div class="grid-item">
                            <h4>3. Peptic Ulcer</h4>
                            <p><strong>Misoprostol ($PGE_1$ analogue):</strong> Prevents NSAID-induced ulcers. (Less effective than PPIs for general ulcer healing).</p>
                        </div>
                        <div class="grid-item">
                            <h4>4. Cardiovascular</h4>
                            <ul>
                                <li><strong>Alprostadil ($PGE_1$):</strong> Keeps ductus arteriosus patent in neonates with congenital heart defects until surgery.</li>
                                <li><strong>Epoprostenol ($PGI_2$):</strong> Pulmonary hypertension, preventing platelet aggregation in dialysis.</li>
                            </ul>
                        </div>
                    </div>

                    <div class="callout callout--tip">
                        <div class="callout-header">
                            <span class="callout-icon">üí°</span>
                            <h4 class="callout-title">Other Uses</h4>
                        </div>
                        <div class="callout-content">
                            <p><strong>Erectile Dysfunction:</strong> Alprostadil injection into corpora cavernosa (largely replaced by Sildenafil).</p>
                        </div>
                    </div>
                </div>
            </section>

            <!-- Section 8: PAF -->
            <section class="content-section" id="paf">
                <div class="section-header">
                    <div class="section-number">08</div>
                    <h2 class="section-title">
                        <span class="title-icon">ü©∏</span>
                        Platelet Activating Factor (PAF)
                    </h2>
                </div>

                <div class="content-card">
                    <p>PAF is an acetylglyceryl ether-phosphoryl choline. It is a potent lipid mediator synthesized by WBC, platelets, and endothelium (not stored).</p>
                    
                    <h3>Actions</h3>
                    <ul class="enhanced-list">
                        <li class="list-item"><strong>Platelets:</strong> Induces aggregation and release reaction (releases $TXA_2$).</li>
                        <li class="list-item"><strong>Inflammation:</strong> Potent chemotactic for neutrophils/eosinophils. Increases vascular permeability (more potent than histamine).</li>
                        <li class="list-item"><strong>Visceral Smooth Muscle:</strong> Bronchoconstriction (long lasting), intestinal contraction.</li>
                        <li class="list-item"><strong>Stomach:</strong> Highly ulcerogenic.</li>
                    </ul>

                    <h3>Pathophysiological Roles</h3>
                    <p>PAF mediates inflammation, bronchial asthma (sustained hyper-reactivity), anaphylactic shock, and thrombosis.</p>
                </div>
            </section>

            <!-- Section 9: Case Study -->
            <section class="content-section" id="case-study">
                <div class="section-header">
                    <div class="section-number">09</div>
                    <h2 class="section-title">
                        <span class="title-icon">ü§î</span>
                        Problem Directed Study
                    </h2>
                </div>

                <div class="content-card">
                    <div class="callout callout--note">
                        <div class="callout-header">
                            <span class="callout-icon">üìù</span>
                            <h4 class="callout-title">Case 13.1</h4>
                        </div>
                        <div class="callout-content">
                            <p>A full term primigravida presented with labour pains... After 8 hours the cervix was still firm and not adequately dilated.</p>
                            <p><strong>(a) Medication for cervix:</strong> Yes. <strong>Prostaglandin $E_2$ (Dinoprostone)</strong> gel can be used for cervical priming (ripening). It softens the cervix and makes it compliant without stimulating strong uterine contractions at low doses. It is applied intracervically or intravaginally.</p>
                            <p><strong>(b) Contraindications:</strong> Based on findings (cephalopelvic disproportion absent, head engaged, fetal heart normal), there are <strong>no specific contraindications</strong> in this case. It should be used with caution, monitoring uterine activity and fetal heart rate.</p>
                        </div>
                    </div>
                </div>
            </section>

        </main>

        <nav class="document-nav">
            <div class="nav-container">
                <a href="topic-13-serotonin.html" class="nav-button nav-button--large nav-button--previous">
                    <div class="nav-label">Previous</div>
                    <div class="nav-title">5-HT, Migraine & Ergot</div>
                </a>
                
                <div class="document-progress">
                    <div class="progress-indicator">
                        <span>14</span>
                        <span class="progress-separator">/</span>
                        <span>20</span>
                    </div>
                    <div class="progress-bar-container">
                        <div class="progress-bar-fill" style="width: 70%;"></div>
                    </div>
                    <div class="progress-label">Topic Progress</div>
                </div>
                
                <a href="topic-15-nsaids.html" class="nav-button nav-button--large nav-button--next">
                    <div class="nav-label">Next</div>
                    <div class="nav-title">NSAIDs & Antipyretics</div>
                </a>
            </div>
        </nav>
    </article>
</div>
</div>

<script src="../js/theme.js"></script>

<script src="../js/navigation.js"></script>

<script src="../js/interactions.js"></script>

</body>
</html>
